secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolent Health, Inc. (EVH)
CIK:        0001628908
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0001628908-25-000018
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolent Q4 2024 revenue $646.5M (+16.3% YoY); net loss $30.6M, adjusted EBITDA $22.6M
--------------------------------------------------------------------------------

- Revenue $2,554.7M full year 2024, +30.1% YoY; net loss $93.5M, net loss margin (3.7)%.
- Adjusted EBITDA $160.5M full year 2024, margin 6.3%; Q4 adjusted EBITDA $22.6M, margin 3.5%.
- Signed contract amendments in all three Performance Suite negotiations, expected $115M annual improvement for 2025 vs Q4 2024.
- 100% retention across top customers representing over 90% of 2024 revenue; new revenue agreements announced in Q4.
- Average Performance Suite lives on platform 7,145 in Q4, average PMPM fee $21.32.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628908/000162890825000018/0001628908-25-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628908/000162890825000018/evh-20250220.htm
  HTML page:      https://secwatch.observer/filing/0001628908-25-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer